Processa Pharmaceuticals, Inc. (PCSA)

1.6000 +0.0700 (+4.58%) At close: 04:00PM EDT

Processa Pharmaceuticals, Inc.

7380 Coca Cola Drive
Suite 106
Hanover, MD 21076
United States
443 776 3133
https://www.processapharmaceuticals.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 13

Key Executives

Name	Title	Pay	Exercised	Year Born
Mr. George K. Ng Esq., J.D.	Chief Executive Officer	400.27k	N/A	1974
Dr. David Young Ph.D., Pharm.D.	Co-Founder, President of Research and Development & Director	160.2k	N/A	1953
Dr. Sian E. Bigora Ph.D., Pharm.D.	Co-Founder and Chief Development & Regulatory Officer	184.87k	N/A	1960
Mr. James H. Stanker	Chief Financial Officer	160.2k	N/A	1958
Mr. Patrick Lin	Co-Founder, Chief Business & Strategy Officer	117.15k	N/A	1965
Ms. Wendy J. Guy	Co-Founder, Chief Administrative Officer & Corporate Secretary	94.19k	N/A	1964

Amounts are as of December 31, 2023 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Processa Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on developing the chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. Its pipeline includes three Chemotherapy drugs, including Capecitabine, PCS6422 and capecitabine to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; Gemcitabine, PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers; and Irinotecan, PCS11T to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. Processa Pharmaceuticals, Inc. was incorporated in 2011 and is based in Hanover, Maryland.

Corporate Governance

Processa Pharmaceuticals, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.